Biogen Inc (BIIB) - Total Assets
Based on the latest financial reports, Biogen Inc (BIIB) holds total assets worth $32.09 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biogen Inc - Total Assets Trend (1985–2025)
This chart illustrates how Biogen Inc's total assets have evolved over time, based on quarterly financial data. Also see Biogen Inc stock valuation for the company's overall valuation and market capitalisation.
Biogen Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Biogen Inc's total assets of $32.09 Billion consist of 30.5% current assets and 69.5% non-current assets. Review Biogen Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.2% |
| Accounts Receivable | $1.87 Billion | 6.3% |
| Inventory | $2.17 Billion | 7.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.18 Billion | 31.2% |
| Goodwill | $6.49 Billion | 22.1% |
Asset Composition Trend (1985–2025)
This chart illustrates how Biogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Biogen Inc (BIIB) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biogen Inc's current assets represent 30.5% of total assets in 2025, a decrease from 66.4% in 1985.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2025, down from 62.4% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 2.0% in 1985.
- Asset Diversification: The largest asset category is intangible assets at 31.2% of total assets.
Biogen Inc Competitors by Total Assets
Key competitors of Biogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NYSE:AZN
|
USA | $115.70 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.71 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
|
China | CN¥41.14 Billion |
Biogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 2.50 | 1.70 |
| Quick Ratio | 1.26 | 1.79 | 1.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.39 Billion | $4.78 Billion | $2.95 Billion |
Biogen Inc - Advanced Valuation Insights
This section examines the relationship between Biogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.67 |
| Latest Market Cap to Assets Ratio | 1.06 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | $29.44 Billion |
| Market Capitalization | $31.14 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Biogen Inc's assets above their book value (1.06x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Biogen Inc's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biogen Inc (1985–2025)
The table below shows the annual total assets of Biogen Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $29.44 Billion | +4.96% |
| 2024-12-31 | $28.05 Billion | +4.49% |
| 2023-12-31 | $26.84 Billion | +9.33% |
| 2022-12-31 | $24.55 Billion | +2.83% |
| 2021-12-31 | $23.88 Billion | -3.01% |
| 2020-12-31 | $24.62 Billion | -9.60% |
| 2019-12-31 | $27.23 Billion | +7.69% |
| 2018-12-31 | $25.29 Billion | +6.92% |
| 2017-12-31 | $23.65 Billion | +3.39% |
| 2016-12-31 | $22.88 Billion | +17.29% |
| 2015-12-31 | $19.50 Billion | +36.24% |
| 2014-12-31 | $14.32 Billion | +20.68% |
| 2013-12-31 | $11.86 Billion | +17.11% |
| 2012-12-31 | $10.13 Billion | +11.94% |
| 2011-12-31 | $9.05 Billion | +11.83% |
| 2010-12-31 | $8.09 Billion | -5.37% |
| 2009-12-31 | $8.55 Billion | +0.86% |
| 2008-12-31 | $8.48 Billion | -1.74% |
| 2007-12-31 | $8.63 Billion | +0.89% |
| 2006-12-31 | $8.55 Billion | +2.22% |
| 2005-12-31 | $8.37 Billion | -8.72% |
| 2004-12-31 | $9.17 Billion | -3.56% |
| 2003-12-31 | $9.50 Billion | +373.54% |
| 2002-12-31 | $2.01 Billion | +16.61% |
| 2001-12-31 | $1.72 Billion | +20.20% |
| 2000-12-31 | $1.43 Billion | +12.04% |
| 1999-12-31 | $1.28 Billion | +38.20% |
| 1998-12-31 | $924.72 Million | +13.63% |
| 1997-12-31 | $813.83 Million | +28.25% |
| 1996-12-31 | $634.57 Million | +35.25% |
| 1995-12-31 | $469.20 Million | +24.17% |
| 1994-12-31 | $377.86 Million | +5.84% |
| 1993-12-31 | $357.00 Million | +14.72% |
| 1992-12-31 | $311.20 Million | +22.96% |
| 1991-12-31 | $253.10 Million | +59.68% |
| 1990-12-31 | $158.50 Million | +9.16% |
| 1989-12-31 | $145.20 Million | +79.48% |
| 1988-12-31 | $80.90 Million | +0.25% |
| 1987-12-31 | $80.70 Million | -20.02% |
| 1986-12-31 | $100.90 Million | +17.60% |
| 1985-12-31 | $85.80 Million | -- |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more